MUSTARD-a comprehensive resource of mutation-specific therapies in cancer.
Journal
Database : the journal of biological databases and curation
ISSN: 1758-0463
Titre abrégé: Database (Oxford)
Pays: England
ID NLM: 101517697
Informations de publication
Date de publication:
26 07 2021
26 07 2021
Historique:
received:
03
08
2020
revised:
22
06
2021
accepted:
28
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
9
11
2021
Statut:
ppublish
Résumé
The steady increase in global cancer burden has fuelled the development of several modes of treatment for the disease. In the presence of an actionable mutation, targeted therapies offer a method to selectively attack cancer cells, increasing overall efficacy and reducing harmful side effects. However, different drug molecules are in different stages of development, with new molecules obtaining approvals from regulatory agencies each year. To augment clinical impact, it is important that this information reaches clinicians, patients and researchers swiftly and in a structured, well-annotated manner. To this end, we have developed Mutation-Specific Therapies Resource and Database in Cancer (MUSTARD), a database that is designed to be a centralized resource with diverse information such as cancer subtype, associated mutations, therapy offered and its effect observed, along with links to external resources for a more comprehensive annotation. In its current version, MUSTARD comprises over 2105 unique entries, including associations between 418 unique drug therapies, 189 cancer subtypes and 167 genes curated and annotated from over 862 different publications. To the best of our knowledge, it is the only resource that offers comprehensive information on mutation-specific, gene fusions and overexpressed gene-targeted therapies for cancer. Database URL: http://clingen.igib.res.in/mustard/.
Identifiants
pubmed: 34309639
pii: 6328507
doi: 10.1093/database/baab042
pmc: PMC8312254
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Council of Scientific and Industrial Research, India
ID : IndiGen (2019)
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Front Oncol. 2017 Sep 19;7:214
pubmed: 28975082
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Front Oncol. 2019 Apr 16;9:263
pubmed: 31058077
J Am Med Inform Assoc. 2017 May 1;24(3):513-519
pubmed: 27789569
Nucleic Acids Res. 2018 Jan 4;46(D1):D1068-D1073
pubmed: 29156001
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Biomedicine (Taipei). 2015 Nov;5(4):19
pubmed: 26613930
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68
pubmed: 26464438
Curr Drug Discov Technol. 2015;12(1):3-20
pubmed: 26033233
Lung Cancer. 2017 May;107:84-90
pubmed: 27346245
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041
pubmed: 31691823
Ann Transl Med. 2019 Nov;7(22):667
pubmed: 31930068
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72
pubmed: 16381955
Nat Genet. 2017 Jan 31;49(2):170-174
pubmed: 28138153
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
J Nat Sci Biol Med. 2016 Jul-Dec;7(2):119-23
pubmed: 27433059
JAMA. 2020 Feb 18;323(7):600
pubmed: 32068804
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Hum Genomics. 2016 Jan 16;10:4
pubmed: 26772741
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640